Medivation spies out immune-oncology territory with CureTech deal

Medivation is venturing into the immune-oncology arena, licensing CureTech's late-stage anti PD-1 monoclonal antibody pidilizumab (CT-011), in an effort to diversify its portfolio, currently dominated by the prostate cancer treatment Xtandi (enzalutamide; licensed to Astellas).